GU Cancers 2019 | Effect of FGFR status on checkpoint inhibitor response in bladder cancer

Tracy Rose

Tracy Rose, MD, of UNC Health Care, Chapel Hill, NC, discusses the effect of FGFR mutations on the treatment responses of bladder cancer patients receiving immune checkpoint blockade therapy. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Rose stresses that further research is required to validate the correlation between FGFR mutations in bladder cancer and responses checkpoint inhibitor therapy.

Share this video